Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
OBJECTIVE
Malignant pleural mesothelioma is known to mimic morphologically a number of diverse reactive and neoplastic conditions. We describe three unusual intraparenchymal growth patterns of malignant mesothelioma seen in a series of 200 malignant pleural mesotheliomas. The diagnostic pitfalls associated with these findings are described and their potential medico-legal implications are highlighted.


RESULTS
The study group comprised 200 malignant pleural mesotheliomas. In each case diagnosis was morphologically confirmed with ancillary immunohistochemistry using a broad panel of both mesothelial and epithelial markers. The patterns of intraparenchymal growth were documented and grouped as: direct subpleural; lymphangitic; and other. The 200 malignant pleural mesotheliomas comprised 118 epithelioid, 57 biphasic and 25 sarcomatoid, subtyped according to the WHO classification. Direct subpleural invasion was seen in 42 cases, lymphangitic spread in 27 cases. Other less well-defined intraparenchymal patterns included three sarcomatoid subtype malignant mesotheliomas exhibiting an intra-alveolar growth pattern mimicking epithelioid haemangioendothelioma. One epithelioid subtype malignant mesothelioma contained an intraparenchymal tumour nodule microscopically comprising lepidic spread of neoplastic cells over maintained alveolar structures mimicking bronchioloalveolar carcinoma. One epithelioid subtype malignant mesothelioma morphologically had areas in which alveoli were distended by discohesive epithelioid neoplastic cells with no interstitial invasion. The appearances mimicked desquamative interstitial pneumonia. Immunohistochemistry played an important role in the definitive diagnosis of each unusual parenchymal tumour deposit. In 126 malignant mesotheliomas no invasion of the subjacent lung parenchyma was identified.


CONCLUSIONS
An awareness of the unusual parenchymal growth pattern in malignant mesothelioma is important to prevent misdiagnosis of other entities. In the medico-legal setting, the presence of epithelioid haemangioendothelioma or bronchioloalveolar carcinoma (in the absence of asbestosis) may be deemed to impact upon the patient's anticipated life expectancy and thereby would decrease the compensation settlement.
Nind
N R
NR
Department of Histopathology, Llandough Hospital, Cardiff and Vale NHS Trust, Cardiff, UK.
Attanoos
R L
RL
Gibbs
A R
AR
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000473:pathology; D014408:Biomarkers, Tumor / Q000378:metabolism; D003937:Diagnosis, Differential; D018323:Hemangioendothelioma, Epithelioid / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D017563:Lung Diseases, Interstitial / Q000473:pathology; D008654:Mesothelioma / Q000145:classification / Q000378:metabolism / Q000556:secondary*; D010994:Pleura / Q000378:metabolism / Q000473:pathology*; D010997:Pleural Neoplasms / Q000145:classification / Q000378:metabolism / Q000473:pathology*
D014408:Biomarkers, Tumor